Abstract
An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have